Literature DB >> 793186

[Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author's transl)].

W Siegmeth, P Placheta.   

Abstract

A double-blind study was carried out to compare the effects of ketoprofen and phenylbutazone in acute gouty arthritis. Two groups of patients, each consisting of 23 males, received intramuscular injections of either phenylbutazone (2 X 300 mg daily) or ketoprofen (2 X 50 mg daily) for a period of 7 days. The drug effects were assessed both subjectively and objectively. There was an excellent therapeutic effect in both groups. In general, no statistically-significant differences were detected between the two preparations. However, ketoprofen appears to be slightly better tolerated with respect to the incidence of systemic and local side effects. Thus, the administration of ketoprofen can be recommended in cases of acute gouty arthritis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 793186

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  3 in total

Review 1.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

Review 2.  Non-steroidal anti-inflammatory drugs for acute gout.

Authors:  Caroline Mpg van Durme; Mihir D Wechalekar; Robert Bm Landewé; Jordi Pardo Pardo; Sheila Cyril; Désirée van der Heijde; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2021-12-09

3.  Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

Authors:  R C Butler; D H Goddard; C S Higgens; P Hollingworth; C T Pease; M A Stodell; J T Scott
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.